Project Grant R01AI192147
Award Date
7/10/25
Completion Date
6/30/30
Dollars Obligated
$369K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92161, USA
Similar Awards
This federal Project Grant award of $2,505,639 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the molecular interactions between lentivirus capsids and the nuclear pore complex protein NUP358. The project aims to investigate how the binding of lentiviral capsids, including HIV-1 and HIV-2, to the RBD4-CHD didomain of NUP358 impacts viral nuclear import and replication....
This Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to enhance understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The awardee, The Regents of the University of California, San Francisco, will conduct biochemical, proteomic, and cellular assays to identify global proteomic changes to ADPR during HIV-1 latency and reactivation,...
This $214,613 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to identify the missing protein or pathway that accounts for the ability of the HIV-1 Nef protein to enhance viral replication and infectivity, independent of the previously identified factors CD4 and SERINC. The research will use proximity proteomics to conduct an open-ended search for novel Nef cofactors or...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $1,583,665 to Boston Medical Center Corporation to investigate the role of defective HIV proviruses in driving persistent inflammation in HIV-infected CD4+ T cells and macrophages. The research aims to: 1) Determine if persistent expression of cryptic HIV-1 RNAs promotes innate immune activities, 2) Examine whether HIV-1 and HIV-2...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on determining the mechanism by which the cellular protein EHD4 decreases the infectivity of HIV-1 virus particles. The $238,972 award to The Research Foundation For The State University Of New York (RF SUNY) aims to: 1) Characterize how EHD4 blocks the incorporation of HIV-1 envelope glycoproteins GP41 and GP120...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA Program 93.855 Allergy and Infectious Diseases Research, is focused on understanding the mechanisms by which the human immune system naturally restricts a specific subset of HIV known as X4-tropic virus. The $197,366 award, effective from March 1, 2025 to February 28, 2030, will support research at Washington University to (1) characterize the molecular mechanisms driving restriction of...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
This Project Grant award of $856,202 was provided by the National Institute of Allergy and Infectious Diseases (NIAID), which oversees the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The award will fund a 5-year study led by researchers at the University of California, San Francisco (UCSF) to investigate the role of IL-10 and IFN signaling in controlling the HIV reservoir and achieving functional HIV cure. The project aims to determine if enhancing IL-10 and...